Glutethimide - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB512244201

Publication Date:

December 3, 2024

Pages:

111

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Glutethimide is a hypnotic sedative drug which is a safe alternative to barbiturates for treatment of insomnia. It mainly used for patients to feel sleepy and make them calm. Glutethimide is highly lipophilic and 听concentrates in adipose tissue and brain. It is an alternative for barbiturates. 听It undergoes extensive metabolism in liver with both unconjugated and conjugated metabolites which kidney excretes. Glutethimide is a CYP2D6 enzyme inducer and when it taken with codeine, it enables the body to convert high amount of codeine to morphine. The most common brand name for glutethimide are ciba, glue, and gofers. It is categorized as schedule II drug under psychotropic substances. Moreover, glutethimide is used to prevent jaundice in newborns and reduce muscle tremors.
The global market for Glutethimide was estimated to be worth US$ 3412.3 million in 2023 and is forecast to a readjusted size of US$ 5151.6 million by 2030 with a CAGR of 5.9% during the forecast period 2024-2030
Glutethimide is a hypnotic sedative drug which is a safe alternative to barbiturates for treatment of insomnia. It mainly used for patients to feel sleepy and make them calm. Glutethimide is highly lipophilic and 听concentrates in adipose tissue and brain. It is an alternative for barbiturates. 听It undergoes extensive metabolism in liver with both unconjugated and conjugated metabolites which kidney excretes. Glutethimide is a CYP2D6 enzyme inducer and when it taken with codeine, it enables the body to convert high amount of codeine to morphine. The most common brand name for glutethimide are ciba, glue, and gofers. It is categorized as schedule II drug under psychotropic substances. Moreover, glutethimide is used to prevent jaundice in newborns and reduce muscle tremors.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Glutethimide, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Glutethimide by region & country, by Type, and by Application.
The Glutethimide market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glutethimide.
麻豆原创 Segmentation
By Company
Pfizer
Abbott Laboratories
Mankind Pharma
Glaxosimithkine
Sanofi
Novartis
Abbvie
Bristol Mayers Squibb
Astrazeneca
Agilent Technologies
Segment by Type:
Tablets
Injection
Capsules
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Glutethimide manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Glutethimide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Glutethimide in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Glutethimide Product Introduction
1.2 Global Glutethimide 麻豆原创 Size Forecast
1.3 Glutethimide 麻豆原创 Trends & Drivers
1.3.1 Glutethimide Industry Trends
1.3.2 Glutethimide 麻豆原创 Drivers & Opportunity
1.3.3 Glutethimide 麻豆原创 Challenges
1.3.4 Glutethimide 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Glutethimide Players Revenue Ranking (2023)
2.2 Global Glutethimide Revenue by Company (2019-2024)
2.3 Key Companies Glutethimide Manufacturing Base Distribution and Headquarters
2.4 Key Companies Glutethimide Product Offered
2.5 Key Companies Time to Begin Mass Production of Glutethimide
2.6 Glutethimide 麻豆原创 Competitive Analysis
2.6.1 Glutethimide 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Glutethimide Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glutethimide as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Tablets
3.1.2 Injection
3.1.3 Capsules
3.2 Global Glutethimide Sales Value by Type
3.2.1 Global Glutethimide Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Glutethimide Sales Value, by Type (2019-2030)
3.2.3 Global Glutethimide Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital Pharmacy
4.1.2 Retail Pharmacy
4.1.3 Online Pharmacy
4.2 Global Glutethimide Sales Value by Application
4.2.1 Global Glutethimide Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Glutethimide Sales Value, by Application (2019-2030)
4.2.3 Global Glutethimide Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Glutethimide Sales Value by Region
5.1.1 Global Glutethimide Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Glutethimide Sales Value by Region (2019-2024)
5.1.3 Global Glutethimide Sales Value by Region (2025-2030)
5.1.4 Global Glutethimide Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Glutethimide Sales Value, 2019-2030
5.2.2 North America Glutethimide Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Glutethimide Sales Value, 2019-2030
5.3.2 Europe Glutethimide Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Glutethimide Sales Value, 2019-2030
5.4.2 Asia Pacific Glutethimide Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Glutethimide Sales Value, 2019-2030
5.5.2 South America Glutethimide Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Glutethimide Sales Value, 2019-2030
5.6.2 Middle East & Africa Glutethimide Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Glutethimide Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Glutethimide Sales Value
6.3 United States
6.3.1 United States Glutethimide Sales Value, 2019-2030
6.3.2 United States Glutethimide Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Glutethimide Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Glutethimide Sales Value, 2019-2030
6.4.2 Europe Glutethimide Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Glutethimide Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Glutethimide Sales Value, 2019-2030
6.5.2 China Glutethimide Sales Value by Type (%), 2023 VS 2030
6.5.3 China Glutethimide Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Glutethimide Sales Value, 2019-2030
6.6.2 Japan Glutethimide Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Glutethimide Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Glutethimide Sales Value, 2019-2030
6.7.2 South Korea Glutethimide Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Glutethimide Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Glutethimide Sales Value, 2019-2030
6.8.2 Southeast Asia Glutethimide Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Glutethimide Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Glutethimide Sales Value, 2019-2030
6.9.2 India Glutethimide Sales Value by Type (%), 2023 VS 2030
6.9.3 India Glutethimide Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Profile
7.1.2 Pfizer Main Business
7.1.3 Pfizer Glutethimide Products, Services and Solutions
7.1.4 Pfizer Glutethimide Revenue (US$ Million) & (2019-2024)
7.1.5 Pfizer Recent Developments
7.2 Abbott Laboratories
7.2.1 Abbott Laboratories Profile
7.2.2 Abbott Laboratories Main Business
7.2.3 Abbott Laboratories Glutethimide Products, Services and Solutions
7.2.4 Abbott Laboratories Glutethimide Revenue (US$ Million) & (2019-2024)
7.2.5 Abbott Laboratories Recent Developments
7.3 Mankind Pharma
7.3.1 Mankind Pharma Profile
7.3.2 Mankind Pharma Main Business
7.3.3 Mankind Pharma Glutethimide Products, Services and Solutions
7.3.4 Mankind Pharma Glutethimide Revenue (US$ Million) & (2019-2024)
7.3.5 Glaxosimithkine Recent Developments
7.4 Glaxosimithkine
7.4.1 Glaxosimithkine Profile
7.4.2 Glaxosimithkine Main Business
7.4.3 Glaxosimithkine Glutethimide Products, Services and Solutions
7.4.4 Glaxosimithkine Glutethimide Revenue (US$ Million) & (2019-2024)
7.4.5 Glaxosimithkine Recent Developments
7.5 Sanofi
7.5.1 Sanofi Profile
7.5.2 Sanofi Main Business
7.5.3 Sanofi Glutethimide Products, Services and Solutions
7.5.4 Sanofi Glutethimide Revenue (US$ Million) & (2019-2024)
7.5.5 Sanofi Recent Developments
7.6 Novartis
7.6.1 Novartis Profile
7.6.2 Novartis Main Business
7.6.3 Novartis Glutethimide Products, Services and Solutions
7.6.4 Novartis Glutethimide Revenue (US$ Million) & (2019-2024)
7.6.5 Novartis Recent Developments
7.7 Abbvie
7.7.1 Abbvie Profile
7.7.2 Abbvie Main Business
7.7.3 Abbvie Glutethimide Products, Services and Solutions
7.7.4 Abbvie Glutethimide Revenue (US$ Million) & (2019-2024)
7.7.5 Abbvie Recent Developments
7.8 Bristol Mayers Squibb
7.8.1 Bristol Mayers Squibb Profile
7.8.2 Bristol Mayers Squibb Main Business
7.8.3 Bristol Mayers Squibb Glutethimide Products, Services and Solutions
7.8.4 Bristol Mayers Squibb Glutethimide Revenue (US$ Million) & (2019-2024)
7.8.5 Bristol Mayers Squibb Recent Developments
7.9 Astrazeneca
7.9.1 Astrazeneca Profile
7.9.2 Astrazeneca Main Business
7.9.3 Astrazeneca Glutethimide Products, Services and Solutions
7.9.4 Astrazeneca Glutethimide Revenue (US$ Million) & (2019-2024)
7.9.5 Astrazeneca Recent Developments
7.10 Agilent Technologies
7.10.1 Agilent Technologies Profile
7.10.2 Agilent Technologies Main Business
7.10.3 Agilent Technologies Glutethimide Products, Services and Solutions
7.10.4 Agilent Technologies Glutethimide Revenue (US$ Million) & (2019-2024)
7.10.5 Agilent Technologies Recent Developments
8 Industry Chain Analysis
8.1 Glutethimide Industrial Chain
8.2 Glutethimide Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Glutethimide Sales Model
8.5.2 Sales Channel
8.5.3 Glutethimide Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Pfizer
Abbott Laboratories
Mankind Pharma
Glaxosimithkine
Sanofi
Novartis
Abbvie
Bristol Mayers Squibb
Astrazeneca
Agilent Technologies

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.